Medical Developments share price halted amid 'significant near-term opportunities'

The company seeks to raise additional capital.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Medical Developments shares are on ice today 
  • The company seeks to raise $30 million to fund growth initiatives 
  • The Medical Developments share price is down more than 42% this year to date 

The Medical Developments International Ltd (ASX: MVP) share price is on ice today following a company requested trading halt.

The ASX granted the trading pause before market open. Prior to being put into the trading halt, the last bid for the Medical Developments share price was $2.40 apiece.

Woman holding out her hand, symbolising a trading halt.

Image source: Getty Images

What was announced?

Medical Developments advised that it will complete a fully underwritten capital raising of $30 million.

This will be comprised of a $15 million placement and a $15 million pro rata accelerated non-renounceable entitlement offer.

It hopes to achieve a cash balance of $49 million post offer to fund three core areas. Per the announcement:

Post transaction MVP's cash balance will be A$49m which will fund:

– continuing execution of the Company's direct sales strategy in the large European
market

– expansion of the Australian business into the emergency sector and further growth in
the ambulance sector

– further investment in business capability to enable global growth

The 1 for 9.5 pro-rata accelerated non-renounceable entitlement offer seeks to raise $15 million. It comes with 1 attaching option to acquire 1 fully paid ordinary share for every 2.5 new shares
issued.

Whereas the placement is targeted towards sophisticated investors with 1 option for every 2.5 new shares issued.

Speaking on the announcement, chairman Gordon Naylor said the company was "pleased with [its] strong revenue growth in FY22and expect this to continue into FY23".

"With a strong funding position following the capital raising, we look forward to investing to continue to deliver on our growth strategy."

The Medical Developments share price is down more than 42% this year to date.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A scientist in a white coat and glasses puts her arms in the air in a sign of strength and success.
Healthcare Shares

Why are Telix Pharmaceuticals shares charging higher today?

A key approval is good news for this drug developer.

Read more »

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Healthcare Shares

Telix Pharmaceuticals shares: FDA approves Pixclara brain cancer drug

Telix Pharmaceuticals’ US FDA approval for Pixclara is a first for glioma imaging, expanding its precision medicine offerings.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

CSL shares just fell 5% after a strong rally. Is the recovery losing steam?

Can CSL’s improving outlook justify its higher share price?

Read more »

ASX share investor sitting with a laptop on a desk, pondering something.
Healthcare Shares

Higher or lower: Where are CSL shares going next?

The biotech giant has been on a tear. Is it too late to invest? Let's find out.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

ASX healthcare shares are 39% higher since June. Are you missing out?

Healthcare stocks endured a long slump before the sector pivoted three months ago.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

EchoIQ shares just crashed 48%. What happens now?

One regulatory letter, half the market cap.

Read more »

young female doctor with digital tablet looking confused.
Healthcare Shares

CSL shares are up 90%. How much higher can they go?

CSL’s recovery could deliver more upside or another sharp reversal.

Read more »

A woman's hair is blown back and her face is in shock at this big news.
Healthcare Shares

Why has this ASX biotech fallen nearly 50% today?

A knockback for a key approval has rocked this company.

Read more »